Featured Story

  • Top 10 animal health companies of 2013

    It is fascinating what has happened in the last couple of years in the animal health industry, which runs to $22 billion a year for animal drugs and vaccines and is expected to grow at 5.7% compound...

Work on the National Bio and Agro-Defense Facility continues

Construction of the $1.25 billion National Bio and Agro-Defense Facility remains on track with the last round of government funding--$300 million--expected to be approved by Congress in next year's budget.

Drug delivery company SiSaf to enter into animal health

SiSaf, a Northern Ireland-based drug delivery company, has announced it plans to enter into the veterinary and animal health sector.

FDA seeks input on conditional approvals for new animal health products

The FDA last week issued two separate notices that it is looking for public comment on how the regulatory agency decides conditional approvals for new animal drugs as well as how it proceeds on giving its okay for combination drugs in medicated feeds.

Avian influenza discovered in NJ results in poultry restrictions in some Asian countries

Taiwan, Japan and Hong Kong announced they have either restricted or suspended the importation of poultry meat, meat products and eggs from Salem County New Jersey after the discovery of low pathogenic H7 avian influenza.

Alivira snaps up 60% stake in Turkey's Provet Veterinary Products

Alivira Animal Health, a joint venture between Shasun Pharmaceuticals and SeQuent Scientific, has grabbed a 60% stake in Turkey's Provet Veterinary Products.


From Our Sister Sites


Merck KGaA has come up with its long-awaited buyout deal, acquiring the life sciences services outfit Sigma-Aldrich for $17 billion. The German Merck is paying $140 a share for Sigma-Aldrich, a...


GlaxoSmithKline and San Diego-based Avalon Ventures have crafted two new biotechs which will explore the therapeutic potential of a pair of new drugs. These companies, dubbed Silarus Therapeutics and Thyritope Biosciences, will each get a $10 million Series A and research support from the venture group and its Big Pharma partner, which will consider whether it wants to snap up the companies once they hit the proof-of-concept stage a few years down the pipeline.